|
|
(54 intermediate revisions by 4 users not shown) |
Line 1: |
Line 1: |
| {{familytree/start}} | | {{familytree/start}} |
| {{familytree | | | | | | | A01 | | | | | | | | | | |A01=[[Atrial flutter]] }} | | {{familytree | | | | | | | | | | | | A01 |-| A02 |-| A03 | | | | |A01=<div style="float: left; text-align: left; padding:1em">'''Confirmed aortic dissection''' <br> ❑ Check whether dissection occurred in ascending aorta </div>|A02=Yes |A03=Consider surgical management}} |
| {{familytree | | | |,|-|-|-|^|-|-|-|.| | | | | | | | }} | | {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | |}} |
| {{familytree | | | B01 | | | | | | B02 | | | | | | |B01=Unstable |B02=Stable }} | | {{familytree | | | | | | | | | | | | B01 | | | | | | | | | | | | |B01=No}} |
| {{familytree | | | |!| | | | | | | |!| | | | | | | | }} | | {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | |}} |
| {{familytree | | | C01 | | | | | | C02 | | | | | | |C01=<div style="float: left; text-align: left; width:25em; padding:1em;">❑ Look for the presence of any of these: <br> | | {{familytree | | | | | | | | | | | | C01 | | | | | | | | | | | | |C01=<div style="float: left; text-align: left; padding:1em">❑ Start Medical management </div>}} |
| :❑ Chronic heart failure
| | {{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | |}} |
| :❑ Hypotension
| | {{familytree | | | | | | | | | | | | D01 | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; padding:1em">❑ Check Vitals <br> |
| :❑ Acute myocardial infarction <br>
| | :❑ Blood pressure in both arms <br> |
| </div>|C02=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> ❑ Administer rate control therapy (AV nodal blockers) <br><br> ''THEN'' <br><br>❑ Attempt conversion
| | :❑ Take the highest reading for treatment or goal therapy <br> |
| :❑ DC cardioversion
| | ❑ Is patient hemodynamically stable ?</div> }} |
| :❑ Atrial pacing
| | {{familytree | | | | | | | | |,|-|-|-|^|-|-|-|-|-|-|-|.| | | | | |}} |
| :❑ Pharmacological cardioversion
| | {{familytree | | | | | | | | E01 | | | | | | | | | | E02 | | | | |E01=Yes |E02=No}} |
| </div> }}
| | {{familytree | | | | | | | | |!| | | | | | | |,|-|-|-|^|-|-|-|.| |}} |
| {{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }} | | {{familytree | | | | | | | | F01 | | | | | | F02 | | | | | | F03 |F01=<div style="float: left; text-align: left; padding:1em">❑ Control rate and pressure<br> |
| {{familytree | | | | | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Assess need for therapy to prevent recurrence </div> |D02=}} | | : ❑ I.V [[Beta blockers]] or [[labetalol]] |
| {{familytree | | | | | | | |!| | | | | | | | | | | | }} | | : ❑ Substitute [[diltiazem]] and [[verapamil]]<br> If [[betablockers]] are contraindicated |
| {{familytree | | | | | | | E01 | | | | | | | | | | |E01=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Administer antiarrythmic therapy to prevent recurrences | |
| ---- | | ---- |
| ❑ Consider catheter ablation if antiarrhythmic therapy fails </div>}} | | ❑ Goal Heart rate should be 60 beats per minute |
| | ---- |
| | ❑ Pain control<br> |
| | : ❑ Use [[Opiates]]</div> |F02=<div style="float: left; text-align: left; padding:1em"> ❑ '''Type A dissection''' |
| | ---- |
| | ❑ Expedited surgical consultation and consider surgery (Urgent)<br> |
| | ❑ Maintain Euvolemic status<br> |
| | : ❑ Intravenous fluid replacement<br> |
| | :❑ Maintain [[mean arterial pressure|mean arterial pressure (MAP)]] of 70 mm of hg<br> |
| | ❑ Rule out complications using imaging study<br> |
| | : ❑ [[Cardiac tamponade|Pericardial tamponade]] |
| | : ❑ [[Aortic rupture|Rupture of aorta]]<br> |
| | : ❑ [[Aortic insufficiency]]</div>|F03=<div style="float: left; text-align: left; padding:1em">❑ Type B dissection |
| | ---- |
| | ❑ Intravenous fluid replacement<br> |
| | : ❑ Maintain [[mean arterial pressure|mean arterial pressure (MAP)]] of 70 mm of hg<br> |
| | ❑ Start vasopressor if still hypotensive |
| | ---- |
| | ❑ Find out etiology of hypertension |
| | :❑ Imaging to find out contained rupture |
| | :❑ Perform [[Echocardiography|Transthoracic echocardiogram (TTE)]] to assess cardiac function |
| | ---- |
| | ❑ Consider surgical evaluation</div> }} |
| | {{familytree | | | | | | | | |!| | | | | | | |!| | | | | | | |!| |}} |
| | {{familytree | | | | | | | | |!| | | | | | | G01 | | | | | | |!| |G01=<div style="float: left; text-align: left; padding:1em">❑ Can the cause of hypotension respond to surgical management</div>}} |
| | {{familytree | | | | | | | | |!| | | |,|-|-|-|^|-|-|-|.| | | |!| |}} |
| | {{familytree | | | | | | | | H01 |-| H02 | | | | | | H03 |-| H04 |H01=<div style="float: left; text-align: left; padding:1em">❑ Monitor vitals closely |
| | : ❑ Maintain systolic BP <120 mm of Hg</div> |H02=No |H03=Yes |H04=Consider surgical management}} |
| | {{familytree | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | | | | | | |}} |
| | {{familytree | | | | I01 | | | | | | I02 | | | | | | | | | | | | |I01=Yes |I02=No}} |
| | {{familytree | | | | |!| | | | | | | |!| | | | | | | | | | | | | |}} |
| | {{familytree | | | | |!| | | | | | | J01 |-|-|-|-|-| J02 | | | | |J01=<div style="float: left; text-align: left; padding:1em"> ❑ Check whether dissection involves ascending aorta</div> |J02=Yes}} |
| | {{familytree | | | | |!| | | | | | | |!| | | | | | | |!| | | | | |}} |
| | {{familytree | | | | |!| | | | | | | K01 | | | | | | |!| | | | | |K01=No}} |
| | {{familytree | | | | |!| | | | | | | |!| | | | | | | |!| | | | | |}} |
| | {{familytree | | | | |`|-|-| L01 |-|-|'| | | | | | | |!| | | | | |L01=<div style="float: left; text-align: left; padding:1em">❑ Control blood pressure |
| | : ❑ Intravenous vasodilator</div>}} |
| | {{familytree | | | | | | | | |!| | | | | | | | | | | |!| | | | | |}} |
| | {{familytree | | | | | | | | M01 | | | | | | | | | | |!| | | | | |M01=<div style="float: left; text-align: left; padding:1em">❑ Monitor vitals closely |
| | : ❑ Maintain systolic BP <120 mm of Hg</div>}} |
| | {{familytree | | | | | | | | |!| | | | | | | | | | | |!| | | | | |}} |
| | {{familytree | | | | | | | | N01 |-| N02 |-| N03 |-|-|'| | | | | |N01=<div style="float: left; text-align: left; padding:1em">❑ Check for any complications which might require surgery |
| | ---- |
| | : ❑ Malperfusion |
| | : ❑ Progressing dissection |
| | : ❑ Expansion of aortic aneurysm |
| | : ❑ [[Hypertension causes|Uncontrolled or refractory hypertension]] </div> |N02=Yes|N03=<div style="float: left; text-align: left; padding:1em">❑ Consider surgical management</div>}} |
| | {{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | |}} |
| | {{familytree | | | | | | | | O01 | | | | | | | | | | | | | | | | |O01=No}} |
| | {{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | |}} |
| | {{familytree | | | | | | | | P01 | | | | | | | | | | | | | | | | |P01=<div style="float: left; text-align: left; padding:1em">❑ Switch to oral medications <br> |
| | :❑ [[Betablockers]] |
| | :❑ Antihypertensive regimen |
| | ---- |
| | ❑ Follow up in the outpatient</div>}} |
| | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | |}} |
| | |
| | ==First Initial Rapid Evaluation of Suspected Aortic Dissection== |
| | Shown below is an algorithm for the First Initial Rapid Evaluation (FIRE) of Aortic dissection. |
| | {{familytree/start}} |
| | {{familytree | | | | | | | | | | A01 | | | | | | | | | | |A01=❑ Identify cardinal signs and symptoms that increase the pretest probability of acute aortic rupture }} |
| | {{familytree | | | | | | | | | | |!| | | | | | | | | | | | }} |
| | {{familytree | | | | | | | | | | B01 | | | | | | | | | | |B01=<div style="text-align: left">❑ Sudden onset chest pain (tearing/ripping/sharp or stabbing)<br> |
| | ❑ Asymmetric blood pressure in extremities<br> |
| | ❑ Shock <br> |
| | ❑ Pulse deficit <br> |
| | ❑ Evolving aortic regurgitation murmur </div>}} |
| | {{familytree | | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | }} |
| | {{familytree | | | | | | C01 | | | | | | C02 | | | | | | |C01=<div style=" background: #F60A0A"> {{fontcolor|#F8F8FF|Unstable patient}} </div>|C02=Stable patient }} |
| | {{familytree | | | | | | |!| | | | | | | |!| | | | | | | | }} |
| | {{familytree | | | | | | D01 | | | | | | D02 | | | | | | |D01=<div style="background: #F60A0A; text-align: left"> {{fontcolor|#F8F8FF|❑ Order urgent TTE <br> ❑ Look for the following high risk features: <br> |
| | :❑ Pericardial effusion <br> |
| | :❑ Regional wall motion abnormality (RWMA) <br> |
| | :❑ Dilated root <br> |
| | :❑ Aortic regurgitation (AR)}} </div> |D02=[[Aortic dissection resident survival guide#Diagnosis|Continue with diagnostic approach]] }} |
| | {{familytree | | | | | | |!| | | | | | | | | | | | | | | | }} |
| | {{familytree | | | | | | E01 | | | | | | | | | | | | | | |E01=<div style=" background: #F60A0A; text-align: left"> {{fontcolor|#F8F8FF|❑ Aortic dissection confirmed |
| | ❑ Transfer to Cardio-thoracic unit |
| | ❑ Perform TEE in CCU or cardiac OR }} </div>}} |
| | {{familytree | | | | | | |!| | | | | | | | | | | | | | | | }} |
| | {{familytree | | | | | | F01 | | | | | | | | | | | | | | |F01=<div style=" background: #F60A0A"> {{fontcolor|#F8F8FF|❑ Proceed to surgery}} </div> }} |
| {{familytree/end}} | | {{familytree/end}} |
|
| |
|
| ==Anticoagulation Therapy==
| | Look for the following: Intimal flap and tear <br> Intimal entry <br> Mobile linear flap in short axis view <br> Small central true lumen communicating with false lumen |
| Shown below are tables depicting the assessment of risk of stroke and the appropriate anticoagulation therapy among patients with Atrial flutter.<ref name="Fuster-2011">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref>
| |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="2"| {{fontcolor|#FFF|Anticoagulation Therapy}}
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''No risk factors''''' ||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aspirin]] 81-325 mg daily'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |'''''1 Moderate risk factor''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Aspirin]] 81-325 mg daily''''' <br> ''OR'' <br> ▸ '''''[[Warfarin]] (INR 2.0 to 3.0, target 2.5)'''''
| |
| |-
| |
| |style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |'''''Any high risk factor or <br> more than 1 moderate risk factor''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Warfarin]] (INR 2.0 to 3.0, target 2.5)'''''
| |
| |-
| |
| |}
| |
| |}
| |
| <br>
| |
| | |
| {| style="cellpadding=0; cellspacing= 0; width: 600px;"
| |
| |-
| |
| | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Low Risk Factors'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Moderate Risk Factors'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''High Risk Factors'''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Female gender'''''<BR>▸ '''''Age 65-74 years'''''<BR> ▸ '''''[[Coronary artery disease]]'''''<BR>▸ '''''[[Thyrotoxicosis]]'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Age ≥ 75 years'''''<BR>▸ '''''[[Hypertension]]'''''<BR> ▸ '''''[[Heart failure]]'''''<BR>▸ '''''LV [[ejection fraction]] ≤ 35%'''''<BR>▸ '''''[[Diabetes mellitus]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Previous [[stroke]], [[TIA]] or [[embolism]]'''''<BR>▸ '''''[[Mitral stenosis]]'''''<BR> ▸ '''''[[Prosthetic heart valve]]'''''
| |
| |-
| |
| |}
| |
| | |
| ===Acute management of atrial flutter===
| |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|Acute management of atrial flutter}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Proposed therapy'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Recommendation'''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''stable flutter'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Conversion''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Atrial or transesophageal pacing'''''<br> or <br>▸ '''''DC cardioversion'''''<br> or <br>▸ '''''Ibutilide'''''<br> or <br>▸ '''''Flecainide'''''<br> or <br>▸ '''''Propafenone'''''<br> or <br>▸ '''''Sotalol'''''<br> or <br>▸ '''''Procainamide'''''<br> or <br>▸ '''''Amiodarone'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Rate control''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Beta blockers]]'''''<br> or <br>▸ '''''[[Verapamil]] or [[diltiazem]]'''''<br> or <br>▸ '''''[[Digitalis]]'''''<br> or <br>▸ '''''[[Amiodarone]]'''''
| |
| |-
| |
| |}
| |
| |}
| |
| | |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|Acute management of atrial flutter}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Proposed therapy'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Recommendation'''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Unstable atrial flutter'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Conversion''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''DC cardioversion'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Rate control''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Beta blockers]]'''''<br> or <br>▸ '''''[[Verapamil]] or [[diltiazem]]'''''<br> or <br>▸ '''''[[Digitalis]]'''''<br> or <br>▸ '''''[[Amiodarone]]'''''
| |
| |-
| |
| |}
| |
| | |
| ===Long term management of atrial flutter===
| |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|Long term management of atrial flutter}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Proposed therapy'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Recommendation'''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''First episode and well-tolerated atrial flutter''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Cardioversion alone''''' <br> or <br> ▸ '''''Catheter ablation'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Recurrent and well-tolerated atrial flutter''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Catheter ablation'''''<br> or <br>▸ '''''Dofetilide'''''<br> or <br>▸ '''''Amiodarone <br>or<br> Sotalol <br>or<br> Flecainide <br>or<br> Quinidine <br>or<br> Propafenone <br>or<br> Procainamide <br>or<br> Disopyramide'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Poorly tolerated atrial flutter''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Catheter ablation'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Atrial flutter appearing after use of class Ic agents or amiodarone for treatment of AF''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Catheter ablation''''' <br> or <br>▸ '''''Stop current drug and use another'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Symptomatic non–CTI-dependent flutter after failed antiarrhythmic drug therapy''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |'''''Catheter ablation'''''
| |
| |-
| |
| |}
| |
| |}
| |
| | |
| ===Pharmacological cardioversion===
| |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="2"| {{fontcolor|#FFF|Pharmacological Cardioversion for Atrial Flutter}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Dosage'''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Flecainide]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence A]]) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral: 200 to 300 mg <br> ▸ Intravenous: 1.5 to 3.0 mg/kg, over 10 to 20 min'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ibutilide]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence A]]) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Intravenous: 1 mg over 10 min, repeat 1 mg if necessary'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propafenone]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence A]]) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral: 600 mg <br> ▸ Intravenous: 1.5 to 2.0 mg/kg, over 10 to 20 min'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]]) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral:'''''
| |
| : '''''Inpatient'''''<br>
| |
| :▸ '''''1.2 to 1.8 g per day in divided dose until a maximum of 10 g '''''<br>
| |
| :▸ '''''Followed by a maintenance dose of 200 to 400 mg per day or 30 mg/kg''''' <br>
| |
| : '''''Outpatient'''''
| |
| :▸ '''''600 to 800 mg per day divided dose until a maximum of 10 g'''''<br>
| |
| :▸ '''''Followed by a maintenance dose of 200 to 400 mg per day ''''' <br>
| |
| ▸ '''''Intravenous:'''''
| |
| : '''''5 to 7 mg/kg, over 30 to 60 min''''' <br> '''''Followed by 1.2 to 1.8 g per day continuous IV''''' <br> ''OR''<br>
| |
| : '''''5 to 7 mg/kg, in divided oral doses until a maximum of 10 g <br> Followe by a maintenance dose of 200 to 400 mg per day'''''
| |
| |-
| |
| |}
| |
| |}
| |
| | |
| ===Antiarrhythmic Therapy===
| |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="2"| {{fontcolor|#FFF|Maintenance of Sinus Rhythm}}
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (100 to 400 mg)'''''<BR>''OR''<BR>▸ '''''[[Disopyramide]] (400 to 750 mg)'''''<BR>''OR''<BR> ▸ '''''[[Dofetilide]] (500 to 1000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Flecainide]] (200 to 300 mg)'''''<BR>''OR''<BR>▸ '''''[[Procainamide]] (1000 to 4000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Propafenone]] (450 to 900 mg)'''''<BR>''OR''<BR>▸ '''''[[Quinidine]] (600 to 1500 mg)'''''<BR>''OR''<BR>▸ '''''[[Sotalol]] (160 to 320 mg)'''''
| |
| |-
| |
| |}
| |
| |}
| |
| | |
| ==Heart Rate Control==
| |
| | |
| Shown below is a table summarizing the list of recommended agents for control of heart rate and their dosages.<ref name="Fuster-2011">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref>
| |
| | |
| {| style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|Heart Rate Control in Acute Setting}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Loading dose''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Maintenance dose'''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control in patients without [[accessory pathway]]'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Esmolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''500 mcg/kg IV over 1 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''60 to 200 mcg/kg/min IV'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.15 mg/kg IV''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2.5 to 5 mg IV bolus over 2 min; up to 3 doses''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''5 to 15 mg/h IV'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.075 to 0.15 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control in patients with [[accessory pathway]]'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart Rate Control in patients with [[heart failure]] and without [[accessory pathway]]'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg IV each 2 h, up to 1.5 mg''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily IV or orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
| |
| |-
| |
| | style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="3"| {{fontcolor|#FFF|'''Heart Rate Control in Non Acute Setting and Long Term Maintenance'''}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart Rate Control in patients with heart failure and without accessory pathway'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 mg by mouth daily''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily, orally'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''800 mg daily for 1 week, orally <br> 600 mg daily for 1 week, orally <br> 400 mg daily for 4 to 6 week, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''200 mg daily, orally'''''
| |
| |-
| |
| |}
| |
| |}
| |